[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-513103-105":59,"doc-detail-513103-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","non-complementbinding-de-novo-donor-specific-anti-hla-antibodies-and-kidney-allograft-survival","Non-Complement–Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival","","C1q-binding capability is evaluated as an indicator of clinical relevance for de novo donor-specific anti-HLA antibodies (DSA) in kidney transplantation. The study determines the incidence and risk factors for C1q-binding de novo DSA and assesses their long-term effect on graft outcome. Screening of 346 nonsensitized recipients using Luminex single antigen flow bead assays identified C1q-binding cases confirmed by a C1q Luminex assay. Results show C1q-binding de novo DSA associate with quicker graft loss after appearance, while persistent C1q-nonbinding de novo DSA can also reduce survival.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-complementbinding-de-novo-donor-specific-anti-hla-antibodies-and-kidney-allograft-survival/513103/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-complementbinding-de-novo-donor-specific-anti-hla-antibodies-and-kidney-allograft-survival/513103.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What are C1q-binding de novo donor-specific anti-HLA antibodies (DSA) and why are they studied?","Question",{"text":112,"@type":113},"They are newly formed anti-HLA antibodies that can bind complement component C1q. The study investigates whether their binding ability signals clinical relevance for kidney graft outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were C1q-binding de novo DSA detected in the study?",{"text":117,"@type":113},"Recipients were screened at 2 and 5 years post-transplant using Luminex Single Antigen Flow Bead assays, and positive findings were followed by a C1q Luminex assay for confirmation.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were associated with increased risk of C1q-binding de novo DSA?",{"text":121,"@type":113},"HLA mismatches and cyclosporine A were independently associated with higher risk of C1q-binding de novo DSA.",{"name":123,"@type":110,"acceptedAnswer":124},"What was the impact of C1q-binding versus C1q-nonbinding de novo DSA on graft survival?",{"text":125,"@type":113},"C1q-binding de novo DSA were associated with graft loss that occurred quickly after their appearance, while persistent C1q-nonbinding de novo DSA could lead to lower long-term graft survival.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},513103,1791429877,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","CLINICAL RESEARCH  \n[www.jasn.org](www.jasn.org)  \nNon-Complement–Binding De Novo Donor-Speciﬁc Anti-HLA Antibodies and Kidney Allograft Survival  \nGwendaline Guidicelli,*†‡ Florent Guerville,†‡§ Sébastien Lepreux,†| Chris Wiebe,¶ Olivier Thaunat,**††‡‡ Valérie Dubois,§§ Jonathan Visentin,*†‡ Thomas Bachelet,†‡§ Emmanuel Morelon,**††‡‡ Peter Nickerson,¶ Pierre Merville,†‡§ Jean-Luc Taupin,*†‡ and Lionel Couzi†‡§  \nDepartments of *Immunology, § Nephrology-Transplantation-Dialysis, and | Histopathology, Bordeaux University Hospital, Bordeaux, France; †Bordeaux University, Bordeaux, France; ‡National Center for Scientiﬁc Research (CNRS), UMR 5164, Bordeaux, France; ¶Department of Medicine and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada; **Transplantation, Nephrology and Clinical Immunology Department, Lyon University Hospital, Lyon, France; ††National Institute for Health and Medical Research (INSERM) U1111, Lyon, France; ‡‡Lyon Est Teaching and Research Unit, Lyon University, Lyon, France; and §§ Histocompatibility Laboratory, French National Blood Service, Lyon, France  \nABSTRACT  \nC1q-binding ability may indicate the clinical relevance of de novo donor-speciﬁc anti-HLA antibodies (DSA) . This study investigated the incidence and risk factors for the appearance of C1q-binding de novo DSA and their long-term impact. Using Luminex Single Antigen Flow Bead assays, 346 pretransplant nonsensitized kidney recipients were screened at 2 and 5 years after transplantation for de novo DSA, which was followed when positive by a C1q Luminex assay. At 2 and 5 years, 12 (3.5%) and eight (2.5%) patients, respectively, had C1q-binding de novo DSA. De novo DSA mean ﬂuorescence intensity.6237 and .10,000 at 2 and 5 years, respectively, predicted C1q binding. HLA mismatches and cyclosporineA were independently associated with increased risk of C1q-binding de novo DSA. When de novo DSA were analyzed at 2 years, the 5-year death-censored graft survival was similar between patients with C1q-nonbinding de novo DSA and those without de novo DSA, but was lower for patients with C1q-binding de novo DSA (P=0.003) . When de novo DSA were analyzed at 2 and 5 years, the 10-year death-censored graft survival was lower for patients with C1q-nonbinding de novo DSA detected at both 2 and 5 years ( P,0.001) and for patients with C1q-binding de novo DSA (P=0.002) than for patients without de novo DSA. These results were partially conﬁrmed in two validation cohorts. In conclusion, C1q-binding de novo DSA are associated with graft loss occurring quickly after their appearance. However, the long-term persistence of C1q-nonbinding de novo DSA could lead to lower graft survival.  \nJ Am Soc Nephrol 27: 615–625, 2016 . doi: 10.1681/ASN.2014040326  \nThe humoralarm ofthe immune system is accountable for most of the decline in kidney allograft function, leading to graft loss.1–3 Donor-speciﬁc antibodies (DSAs) identiﬁed before transplantation in patients already sensitized are associated with early antibody-mediated rejection (AMR) and poorer graft survival. 4,5 Alternatively, de novo DSAs (dnDSAs) emerge after transplantation in 13%–27% of previously nonsensitized recipients  \nReceived April 3, 2014 . Accepted April 24, 2015 .  \nF.G., G.G., J. L.T., and L.C. contributed equally to this work.  \nPublished online ahead of print. Publication date available at [www.jasn.org](www.jasn.org).  \nCorrespondence: Dr. Lionel Couzi, Centre Hospitalier Universitaire de Bordeaux–Hôpital Pellegrin, Service de Néphrologie-Transplantation-Dialyse, Place Amélie Raba Léon, 33076 Bordeaux, France. Email: [lionel.couzi@chu-bordeaux.fr](lionel.couzi@chu-bordeaux.fr)  \nCopyright © 2016 by the American Society of Nephrology  \nJ Am Soc Nephrol 27: 615–625, 2016 ISSN : 1046-6673/2702-615 615  \n\n| CLINICAL RESEARCH | [www.jasn.org](www.jasn.org) |\n| --- | --- |\n\nwhen detected with current highly sensitive single-antigen ﬂow beads (SAFB) assays.6,7 They mostly appear during the ﬁrst","cbCaikgqZimYuQ5m","https://ap.wps.com/l/cbCaikgqZimYuQ5m","pdf",1303619,11,"English","# Abstract\n## Study design and screening\n## Incidence of C1q-binding de novo DSA\n## Risk factors and graft survival impact\n## Conclusions and validation","[{\"question\":\"What are C1q-binding de novo donor-specific anti-HLA antibodies (DSA) and why are they studied?\",\"answer\":\"They are newly formed anti-HLA antibodies that can bind complement component C1q. The study investigates whether their binding ability signals clinical relevance for kidney graft outcomes.\"},{\"question\":\"How were C1q-binding de novo DSA detected in the study?\",\"answer\":\"Recipients were screened at 2 and 5 years post-transplant using Luminex Single Antigen Flow Bead assays, and positive findings were followed by a C1q Luminex assay for confirmation.\"},{\"question\":\"Which factors were associated with increased risk of C1q-binding de novo DSA?\",\"answer\":\"HLA mismatches and cyclosporine A were independently associated with higher risk of C1q-binding de novo DSA.\"},{\"question\":\"What was the impact of C1q-binding versus C1q-nonbinding de novo DSA on graft survival?\",\"answer\":\"C1q-binding de novo DSA were associated with graft loss that occurred quickly after their appearance, while persistent C1q-nonbinding de novo DSA could lead to lower long-term graft survival.\"}]","Non-Complement–Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival | PDF",1791280135,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/906b6d03195f1f7b194bc35b7c094396.webp",983,1315,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/0a2e21dcd5a1898f78940f479d70c4b3.webp",982,1314,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/0fb2f07b78052295093e4f4a6ae29c24.webp",981,1312,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/87eb0c3cd647f473663540f9d2ebf107.webp",980,1311]